Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030432 · ClinicalTrials.gov registry record · Phase 2
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT01030432 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 285 participants.
The verdict
NCT01030432, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).
Interventions
- DRUG Placebo
- DRUG BMS-650032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030432
The ClinicalTrials.gov registry entry for NCT01030432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01030432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01030432 about?
NCT01030432 is a clinical study titled "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin". The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).
What is the current status of trial NCT01030432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2010-02. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01030432?
The interventions under investigation include: Placebo (DRUG), BMS-650032 (DRUG).
Who is sponsoring clinical trial NCT01030432?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.